Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
A.2NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
A.2NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.533NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.533NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.533NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
AY.120.2 (Delta)NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
AY.120.2 (Delta)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
AY.120.2 (Delta)NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.1.528NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.528NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.528NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
C.1.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
C.1.2NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
C.1.2NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
AY.91 (Delta)NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
AY.91 (Delta)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
AY.91 (Delta)NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.3NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.3NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.3NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.39NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.39NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.39NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.617NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.617NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.617NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.1.383NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.383NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.383NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.1.40NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.40NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.40NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
AY.95 (Delta)NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
AY.95 (Delta)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
AY.95 (Delta)NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.1.189NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.189NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.189NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
BA.1.13NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.1.13NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BA.1.13NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
C.13NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
C.13NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
C.13NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
C.4NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
C.4NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
C.4NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.545NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.545NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.545NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used